- Home
- MAMA vs EDIT Comparison
MAMA vs EDIT Comparison
Compare MAMA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- EDIT
- Stock Information
- Founded
- MAMA 2010
- EDIT 2013
- Country
- MAMA United States
- EDIT United States
- Employees
- MAMA N/A
- EDIT N/A
- Industry
- MAMA Specialty Foods
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAMA Consumer Staples
- EDIT Health Care
- Exchange
- MAMA Nasdaq
- EDIT Nasdaq
- Market Cap
- MAMA 323.1M
- EDIT 263.7M
- IPO Year
- MAMA N/A
- EDIT 2016
- Fundamental
- Price
- MAMA $9.45
- EDIT $2.77
- Analyst Decision
- MAMA Strong Buy
- EDIT Buy
- Analyst Count
- MAMA 3
- EDIT 12
- Target Price
- MAMA $10.33
- EDIT $5.40
- AVG Volume (30 Days)
- MAMA 197.2K
- EDIT 1.8M
- Earning Date
- MAMA 09-08-2025
- EDIT 11-03-2025
- Dividend Yield
- MAMA N/A
- EDIT N/A
- EPS Growth
- MAMA N/A
- EDIT N/A
- EPS
- MAMA 0.11
- EDIT N/A
- Revenue
- MAMA $128,745,000.00
- EDIT $38,901,000.00
- Revenue This Year
- MAMA $17.24
- EDIT N/A
- Revenue Next Year
- MAMA $9.95
- EDIT N/A
- P/E Ratio
- MAMA $85.85
- EDIT N/A
- Revenue Growth
- MAMA 17.04
- EDIT N/A
- 52 Week Low
- MAMA $5.50
- EDIT $0.91
- 52 Week High
- MAMA $9.98
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- MAMA 66.51
- EDIT 54.20
- Support Level
- MAMA $9.20
- EDIT $2.39
- Resistance Level
- MAMA $9.63
- EDIT $2.72
- Average True Range (ATR)
- MAMA 0.40
- EDIT 0.16
- MACD
- MAMA 0.15
- EDIT -0.00
- Stochastic Oscillator
- MAMA 85.15
- EDIT 70.62
About MAMA Mama's Creations Inc.
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.